Article info

Download PDFPDF

Original research
Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial

Authors

  • Byeong-zu Ghang Rheumatology, Jeju National University College of Medicine and Graduate School of Medicine, Jeju National University Hospital, Jeju, The Republic of Korea PubMed articlesGoogle scholar articles
  • Ji Sung Lee Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, The Republic of KoreaClinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, The Republic of Korea PubMed articlesGoogle scholar articles
  • Jihye Choi Rheumatology, Jeju National University College of Medicine and Graduate School of Medicine, Jeju National University Hospital, Jeju, The Republic of Korea PubMed articlesGoogle scholar articles
  • Jinseok Kim Rheumatology, Jeju National University College of Medicine and Graduate School of Medicine, Jeju National University Hospital, Jeju, The Republic of Korea PubMed articlesGoogle scholar articles
  • Bin Yoo Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, The Republic of Korea PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Bin Yoo; byoo{at}amc.seoul.kr; Professor Jinseok Kim; slera{at}jejunu.ac.kr
View Full Text

Citation

Ghang B, Lee JS, Choi J, et al
Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial

Publication history

  • Received September 17, 2021
  • Accepted May 4, 2022
  • First published June 22, 2022.
Online issue publication 
June 22, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.